FibroGen CKD therapy clears Phase III hurdle in China

FibroGen Inc. (NASDAQ:FGEN) said roxadustat (FG-4592) met the primary endpoints in two Chinese Phase III trials to treat anemia in chronic kidney disease (CKD)

Read the full 243 word article

User Sign In